Clinical trial · Observational
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)
NCT07653126CI-TRIAL-00115146LUNET-2completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastro-enteropancreatic Neuroendocrine Tumor | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- PRRT Cohort
- description
- Adult GEP-NET patients who received PRRT in German routine care.
Primary outcomes (8)
- measure
- Baseline Demographics
- timeFrame
- Baseline
- measure
- Number of Patients by Tumor Status
- timeFrame
- Baseline
- measure
- Duration Between Initial Diagnosis and Initiation of Primary PRRT
- timeFrame
- Baseline
- measure
- Number of Patients by PRRT Line of Therapy
- timeFrame
- Approximately 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade). * Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021. Exclusion criteria: * Received a combination of PRRT with chemotherapy. * Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
References
Publications (0)
Data not yet available
No reference posted for this study.